About: Vaccination with recombinant adenovirus expressing multi-stage antigens of Toxoplasma gondii by the mucosal route induces higher systemic cellular and local mucosal immune responses than with other vaccination routes

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Vaccination with recombinant adenovirus expressing multi-stage antigens of Toxoplasma gondii by the mucosal route induces higher systemic cellular and local mucosal immune responses than with other vaccination routes Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Vaccination with recombinant adenovirus expressing multi-stage antigens of Toxoplasma gondii by the mucosal route induces higher systemic cellular and local mucosal immune responses than with other vaccination routes
Creator	Li, Yan Wang, Ting Cong, Hua Sun, Xiahui Yin, Huiquan Zhao, Lingxiao
Source	Medline; PMC
abstract	Toxoplasmosis caused by Toxoplasma gondii, an obligate intracellular protozoan, is a cause of congenital disease and abortion in humans and animals. Various vaccination strategies against toxoplasmosis in rodent models have been used in the past few decades; however, effective vaccines remain a challenge. A recombinant adenovirus vaccine expressing ubiquitin-conjugated multi-stage antigen segments (Ad-UMAS) derived from different life-cycle stages of T. gondii was constructed previously. Here, we compared the immune responses and protection effects in vaccination of mice with Ad-UMAS by five vaccination routes including intramuscular (i.m.), intravenous (i.v.), subcutaneous (s.c.), intraoral (i.o.), and intranasal (i.n.). Much higher levels of T. gondii-specific IgG and IgA antibodies were detected in the sera of the intraoral and intranasal vaccination groups on day 49 compared with controls (p < 0.05). The percentages of CD8(+) T-cells in mice immunized intranasally and intraorally were larger than in mice immunized intramuscularly (p < 0.05). The highest level of IL-2 and IFN-γ was detected in the group with nasal immunization, and splenocyte proliferation activity was significantly enhanced in mice immunized via the oral and nasal routes. Furthermore, the higher survival rate (50%) and lower cyst numbers observed in the intraoral and intranasal groups all indicate that Ad-UMAS is far more effective in protecting mice against T. gondii infection via the mucosal route. Ad-UMAS could be an effective and safe mucosal candidate vaccine to protect animals and humans against T. gondii infection.
has issue date	2017-04-03(xsd:dateTime)
bibo:doi	10.1051/parasite/2017013
bibo:pmid	28367800
has license	cc-by
sha1sum (hex)	2f446f5b176d426f14b28a4898d83c43291ae82d
schema:url	https://doi.org/10.1051/parasite/2017013
resource representing a document's title	Vaccination with recombinant adenovirus expressing multi-stage antigens of Toxoplasma gondii by the mucosal route induces higher systemic cellular and local mucosal immune responses than with other vaccination routes
has PubMed Central identifier	PMC5399536
has PubMed identifier	28367800
schema:publication	Parasite
resource representing a document's body	covid:2f446f5b176d426f14b28a4898d83c43291ae82d#body_text
is schema:about of	named entity 'group' named entity 'expressing' named entity 'vaccine' named entity 'CD8' named entity 'life-cycle' named entity 'route' named entity 'infection' named entity 'level' named entity 'routes' named entity 'immunized' named entity 'vaccination' named entity 'higher' named entity 'antigens' named entity 'MUCOSAL' named entity 'RECOMBINANT ADENOVIRUS' named entity 'MODELS' named entity 'INTRAVENOUS' named entity 'INFECTION' named entity 'LEVELS' named entity 'CONJUGATED' named entity 'VACCINES' named entity 'NASAL' named entity 'LEVEL' named entity 'SPLENOCYTE' named entity 'PROLIFERATION' named entity 'GROUP' named entity 'IMMUNIZATION' named entity '28P' named entity 'COMPARED' named entity 'SPECIFIC' named entity 'UBIQUITIN' named entity 'MUCH' named entity 'IGA' named entity 'CAUSE' named entity 'INTRAMUSCULAR' named entity 'DETECTED' named entity 'STRATEGIES' named entity 'CONSTRUCTED' named entity 'STAGE' named entity 'RECOMBINANT ADENOVIRUS' named entity 'PROTECTION' named entity 'T-CELLS' named entity 'VACCINE' named entity 'ENHANCED' named entity 'EFFECTS' named entity 'SEGMENTS' named entity 'DERIVED' named entity 'IFN' named entity 'HERE' named entity 'IMMUNE RESPONSES' named entity 'ROUTES' named entity 'EFFECTIVE' named entity 'IS A' named entity 'CHALLENGE' named entity 'TOXOPLASMA GONDII' named entity 'CD8' named entity 'HIGHER' named entity 'ANIMALS' named entity 'LOWER' named entity 'ROUTE' named entity 'HIGHEST' named entity 'CANDIDATE' named entity 'ORAL' named entity 'CELLULAR' named entity 'LOCAL' named entity 'STAGE' named entity 'ANTIGENS' named entity 'USED' named entity 'COULD BE' named entity 'HAVE' named entity '28I' named entity 'ACTIVITY' named entity 'PROTOZOAN' covid:arg/2f446f5b176d426f14b28a4898d83c43291ae82d named entity 'HUMANS' named entity 'IGG'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software